Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis
Amphastar’s depressed 6.65x forward P/E masks a high-barrier proprietary and biosimilar pivot, but IMS remediation and balance-sheet pressure make 2027 execution the decisive rerating catalyst.
Overview
Amphastar Pharmaceuticals is a specialized biopharmaceutical company developing, manufacturing, and commercializing technically difficult generic and proprietary injectable, inhalation, intranasal, and drug-device products. Its moat comes from complex regulatory and clinical requirements, vertical API integration through ANP, and differentiated delivery systems. The business is undergoing a significant mix transition: enoxaparin fell from 51% of revenue in 2014 to approximately 15% in 2025, while adjusted net-income margin expanded from 3.5% in 2018 to 21.8% in fiscal 2025. **Q2 2026 showed improving product mix**, with revenue up 5.4% year over year to $183.9 million, gross margin rising to 50.8%, and adjusted EPS of $0.91 versus $0.62 consensus. Still, IMS CGMP remediation may cost $2.0–$3.0 million per quarter and affect a facility generating roughly one-third of revenue, while a $100.0 million BAQSIMI milestone is due to Eli Lilly in Q3 2026. The stock trades at 12.2x trailing and 6.65x forward P/E, with consensus targets near $20–$22. **The valuation opportunity depends on 2027 AMP-004 insulin-aspart and AMP-018 GLP-1 launches**, which could support a rerating toward specialty biopharma multiples.